

BIOMYLZ PRIVATE LIMITED
Balance Sheet as at March 31, 2025

(Amount in Rs. 000's)

Particulars	Note	As at March 31, 2025	As at March 31, 2024
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	3	500.00	500.00
Reserves and Surplus	4	77,153.42	67,854.66
		77,653.42	68,354.66
Non-Current Liabilities			
Long-Term Borrowings	5	1,30,119.80	1,41,488.42
		1,30,119.80	1,41,488.42
Current Liabilities			
Short-Term Borrowings	6	22,838.65	30,668.35
Trade Payables	7	99,508.71	1,33,222.95
Other Current Liabilities	8	18,155.58	37,925.49
Short-Term Provisions	9	4,373.60	7,744.04
		1,44,876.54	2,09,560.83
TOTAL		3,52,649.76	4,19,403.92
ASSETS			
Non-Current Assets			
Property, Plant and Equipment & Intangible Assets	10		
Property, Plant and Equipment		70,140.08	62,150.71
Intangible Assets		26.53	172.21
Deferred tax assets (net)	11	1,587.22	470.03
Long-Term Loans and Advances	12	10,333.05	10,333.05
Other Non-Current Assets	13	2,100.00	2,100.00
		84,186.87	75,226.00
Current Assets			
Inventories	14	1,71,967.26	2,03,139.57
Trade Receivables	15	44,382.54	79,517.39
Cash and Cash Equivalents	16	3,842.31	23,026.95
Other Current Assets	17	48,270.75	38,493.99
		2,68,462.87	3,44,177.90
TOTAL		3,52,649.76	4,19,403.92
Notes forming part of the Accounts	1-35		

As per our report of even date

For Venkatesh & Raghavendra

Chartered Accountants

Firm Regn No : 0193675


CA Raghavendra D
Partner

Membership No. 212056

UDIN: 25212056BMJTMZ6473

Place : Bengaluru

Date : 22-09-2025

For and on behalf of the Board of

Biomylyz Private Limited

For BioMylz Pvt. Ltd.


Vasanth Samaga
Director

DIN: 07321429

For BioMylz Pvt. Ltd.


Srisailan Krishnamurthy
Director

DIN : 03614475

BIOMYLZ PRIVATE LIMITED

Statement of Profit and Loss for the year ended March 31, 2025

(Amount in Rs. 000's)

Particulars	Note	For the year ended March 31, 2025	For the year ended March 31, 2024
INCOME			
Revenue from Operations	18	7,00,385.87	5,86,349.68
Other Income	19	4,633.97	-
Total Income		7,05,019.84	5,86,349.68
EXPENSES			
Cost of Raw Material Consumed	20	4,08,206.65	3,40,169.44
(Increase)/Decrease of Finished Goods & WIP	21	(25,447.61)	(26,123.27)
Employee Benefits Expense	22	52,317.99	45,190.84
Finance Costs	23	9,593.25	10,256.28
Depreciation, Amortisation and Impairment	24	13,999.39	13,054.73
Other Expenses	25	2,32,865.22	1,76,540.46
Total Expenses		6,91,534.90	5,59,088.49
Profit before Tax		13,484.94	27,261.18
Tax expense:			
Current Tax		4,900.00	9,200.00
Tax of Earlier Years		403.37	-
Deferred tax (credit)/ charge		(1,117.18)	430.69
Profit for the Period		9,298.76	17,630.49
Earnings per Equity Share:			
Basic & Diluted (Amount in Rupees)	27	185.98	352.61
Notes forming part of the Accounts	1-35		

As per our report of even date

For Venkatesh & Raghavendra

Chartered Accountants

Firm Regn No : 019367S


CA Raghavendra D
 Partner
 Membership No. 212056
 UDIN: 25212056BMJTMZ6473



For and on behalf of the Board of
Biomyz Private Limited

For BioMylz Pvt. Ltd.


Vasanth Samaga
 Director
 DIN: 07321429

For BioMylz Pvt. Ltd.


Srisailan Krishnamurthy
 Director
 DIN : 03614475

Place : Bengaluru

Date : 22-09-2025

BIOMYLZ PRIVATE LIMITED

Statement of cash flows for the year ended March 31, 2025

(Amount in Rs. 000's)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Cash flow from operating activities		
Profit/(Loss) before taxes	13,484.94	27,261.18
Adjustments for :		
Depreciation and amortisation	13,999.39	13,054.73
Interest expenses	8,793.10	9,069.26
	36,277.43	49,385.17
Adjustments for :		
(Increase)/decrease in loans and advances	(9,776.77)	15,388.14
(Increase)/ decrease in inventories	31,172.31	(1,09,333.44)
(Increase)/ decrease in trade receivables	35,134.85	19,507.17
(Increase)/decrease in other non current assets	-	-
Increase/(decrease) in trade payables	(33,714.24)	42,495.67
Increase/(decrease) in provisions	-	253.33
Increase/(decrease) in other current liabilities	(19,769.91)	22,829.36
	3,046.23	(8,859.77)
Refund/(payment) of direct taxes	(8,673.81)	(9,200.00)
Net cash flow from/(used in) operating activities - (a)	(5,627.58)	(18,059.77)
Cash flow from investing activities		
Purchase of Property, Plant and Equipment	(21,843.08)	(8,679.38)
Net cash used in investing activities - (b)	(21,843.08)	(8,679.38)
Cash flow from financing activities		
Increase/(Repayment) of Borrowings	(19,198.32)	(767.93)
Interest expenses	(8,793.10)	(9,069.26)
Net cash generated from/(used in) financing activities - (c)	(27,991.42)	(9,837.19)
Net increase/(decrease) in cash and cash equivalents - (a)+(b)-	(55,462.08)	(36,576.34)
Net increase/(decrease) in cash and cash equivalents	(19,185)	12,808.82
Cash and cash equivalents at beginning of the year	23,026.95	10,218.13
Cash and cash equivalents at end of the year	3,842.31	23,026.95
Reconciliation with Cash & Bank Balance as per Balance Sheet		
Cash & Bank Balance as per Balance Sheet	3,842.31	23,026.95
Cash and cash equivalents at end of the year	3,842.31	23,026.95

As per our report of even date

For Venkatesh & Raghavendra

Chartered Accountants


Firm Regn No : 0193675


CA Raghavendra D
Partner
Membership No. 212056
UDIN: 25212056BMJTMZ6473

For and on behalf of the Board of

BiomyLz Private Limited

For BioMylz Pvt. Ltd.


Vasanth Samaga
Director
DIN: 07321429

For BioMylz Pvt. Ltd.


Srisailan Krishnamurthy
Director
DIN : 03614475

Place : Bengaluru

Date : 22-09-2025

BIOMYLZ PRIVATE LIMITED
Notes to Financial Statements for the year ended March 31, 2025

1 General Information

Biomylz Private Limited ('the Company') was incorporated on 1st March 2017 with its registered office in Bengaluru, India under the provisions of the Companies Act, 2013 having CIN - U33208KA2017PTC100964.

The Company is engaged in manufacturing of Probiotics, Nutraceutical food supplement and cosmetics finished formulation. Founded as manufacturer of wide range of premium dietary supplement products, BioMylz manufactures and markets an array of natural medicines and healthcare products for effective causal treatment combined with maximum tolerability. As a Neutral Label, Contract manufacturer, BioMylz has a good clarity on regulatory registration requirement of importing countries.

2 Significant accounting policies

2.1 Basis of preparation of financial statements

The financial statements are prepared in accordance with the generally accepted accounting principles in India ("Indian GAAP") under the historical cost convention on an accrual basis. The financial statements comply in all material respects with the accounting standards ("AS") as specified under Section 133 of the Companies Act, 2013 (the 'Act') read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended). The accounting policies adopted in the preparation of financial statements are consistent with those used in the previous period.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in Schedule III to the Act. Based on the nature of services and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

2.2 Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management, where necessary, to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised. Any revision to accounting estimates are recognised prospectively. Significant estimates used by management in the preparation of these financial statements include the estimates of the economic useful lives of tangible assets, provision for taxation, provision for doubtful debts and advances.

2.3 Revenue recognition

Sale of goods

Sales are recognised when the significant risks and rewards of ownership have been transferred to the buyer and the Company retains no effective control of the goods transferred and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods. Sales are recognised net of trade discounts, rebates and indirect taxes.

Service income

Service income is accounted as and when services are rendered and net of indirect taxes.

2.4 Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the first-in first out formula, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their present location and condition.

2.5 Property, plant and equipment

Property, Plant and Equipment are stated at cost less accumulated depreciation. Cost includes all expenses, direct and indirect, specifically attributable to its acquisition and bringing it to its working condition for its intended use.

2.6 Depreciation

Depreciation is provided under the straight-line (SLM) method, based on the estimated useful life of the assets. Depreciation is calculated on a pro-rata basis from the date of installation till the date the assets are sold or disposed. The Management estimates the useful lives of the assets as per the indicative useful life prescribed in Schedule II to the Companies Act, 2013.



BIOMYLZ PRIVATE LIMITED
Notes to Financial Statements for the year ended March 31, 2025

Asset category	Useful life (years)
Computers and data processing equipments	3
Furniture and fixtures	10
Leased premises	30
Plant and machinery	15
Office equipment	5
Softwares	3

2.7 Impairment of assets

The carrying amounts of the Company's assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the assets' recoverable amount is estimated as higher of the net selling price and value in use. An impairment loss is recognised in the Statement of Profit and Loss, whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. An impairment loss is reversed if there has been change in the recoverable amount and such loss either no longer exists or has decreased.

2.8 Foreign currency transactions

Initial recognition

Foreign currency transactions are recorded at the exchange rate prevailing on the date of the transaction. Differences arising out of foreign currency transactions settled during the year are recognised in the Statement of Profit and Loss.

Conversion

Monetary items outstanding at the Balance Sheet date and denominated in foreign currencies are recorded at the exchange rate prevailing at the end of the financial year. Differences arising there from are recognised in the Statement of Profit and Loss.

2.9 Earnings/ (loss) per share

Basic earnings/(loss) per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings/(loss) per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

2.10 Employee benefits

Short-term employee benefits are recognized as an expense at the undiscounted amount in the profit and loss account of the year in which the related service is rendered.

Defined contribution plan

The Company contributes towards defined contribution plans including provident fund and employees state insurance as per the requirements of the respective Acts.

2.11 Income tax expense

Current tax

Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.



BIOMYLZ PRIVATE LIMITED
Notes to Financial Statements for the year ended March 31, 2025

Deferred tax

Deferred tax charge or credit reflects the tax effect of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each Balance Sheet date and written down or written-up to reflect the amount that is reasonably / virtually certain (as the case may be) to be realised.

The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.

Unrecognised deferred tax assets of earlier years are re-assessed and recognised to the extent that it has become reasonably certain that future taxable income will be available against which such deferred tax assets can be realised.

2.12 Provisions and contingencies

Provisions are recognized only when there is a present obligation as a result of past events, the settlement of which is expected to result in an outflow of resources embodying economic benefits, and when a reliable estimate of the amount of obligation can be made. Contingent liability is disclosed for


- (i) possible obligation which will be confirmed only by future events not wholly within the control of the Company or
- (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent assets are not recognized in the financial statements since this may result in the recognition of income that may never be realized.

2.13 Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes if any) by the weighted average number of equity shares outstanding during the period. Partly paid equity shares (if any) are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period ended for nine months are adjusted for events of bonus issue; bonus element in a rights issue to existing shareholders; share split; and consolidation of shares if any.

For the purpose of calculating diluted earnings per share, the net profit or loss for the nine months period attributable to equity shareholders and the weighted average number of shares outstanding during the nine months period are adjusted for the effects of all dilutive potential equity shares.

This space is intentionally left blank



BIOMYLZ PRIVATE LIMITED
Notes to the Balance Sheet as at March 31, 2025

3 Share capital	As at March 31, 2025	As at March 31, 2024
<u>Authorised Capital</u>		
1,00,000 (P.Y. 1,00,000) Equity Shares of Rs.10 each	1,000.00	1,000.00
<u>Issued, Subscribed, Paid-up Capital</u>		
50,000 (P.Y. 50,000) Equity Shares of Rs.10 each fully Paid up	500.00	500.00
Total Issued, Subscribed and Paid-up share capital	500.00	500.00

a) Reconciliation of the Shares outstanding at the beginning and at the end of the reporting period

Particulars	As at March 31, 2025 & March 31, 2024	
	Number of shares	Amount
Shares outstanding at the beginning of the year	50,000	500.00
Shares outstanding at the end of the year	50,000	500.00

b) Terms /Rights attached to Equity Shares

Equity Shares: The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation the holders of equity shares will be entitled to receive remaining assets of the company after payment of all liabilities. Distribution will be based on number of equity shares held by the shareholder.

c) Company does not have any holding company or subsidiary company, hence details of shares held by holding and subsidiary company does not arise.

d) Details of Shareholders holding more than 5% Shares in the Company

Name of the Share Promoter	March 31, 2025		March 31, 2024	
	Nos	Percentage	Nos	Percentage
Rahul N Reddy	10,000	20%	10,000	20%
Padmavathi	10,000	20%	10,000	20%
Srisailan Krishnamurthy	10,000	20%	10,000	20%
Vasanth Samaga	10,000	20%	10,000	20%
Srinivasa Raghavendra	10,000	20%	10,000	20%

As per the records of the company and other declarations received from shareholders regarding beneficial interest, above shareholdings represent both legal and beneficial ownership of shares.

e) Shareholding of Promoters


Name of the Share Promoter	March 31, 2025		March 31, 2024	
	Nos	Percentage	Nos	Percentage
Rahul N Reddy	10,000	20%	10,000	20%
Padmavathi	10,000	20%	10,000	20%
Srisailan Krishnamurthy	10,000	20%	10,000	20%
Vasanth Samaga	10,000	20%	10,000	20%
Srinivasa Raghavendra	10,000	20%	10,000	20%

There are no change in % of holding by promoters during the year

f) During any of the last five years from year ended March 31, 2025 :

- No shares were allotted as fully paid up pursuant to contract(s) without payment being received in cash
- No shares were allotted as fully paid up by way of bonus shares
- The Company has not bought back shares issued.

4 Reserves and Surplus	As at March 31, 2025	As at March 31, 2024
Surplus in Profit and Loss account		
Opening Balance	67,854.66	50,224.17
Add : Profit for the year	9,298.76	17,630.49
Total	77,153.42	67,854.66



BIOMYLZ PRIVATE LIMITED
Notes to the Balance Sheet as at March 31, 2025

5 Long Term Borrowings	As at March 31, 2025	As at March 31, 2024
<u>Secured Borrowings from</u>		
-Other Financial Institutions *	13,472.01	20,530.54
<u>Unsecured Borrowings from</u>		
-Banks **	14,493.00	20,770.18
-Other Financial Institutions ***	19,578.95	25,441.56
-Directors ****	1,05,414.50	1,05,414.50
	1,52,958.45	1,72,156.77
Less : Current maturities disclosed under short term borrowings - in Note 6	(22,838.65)	(30,668.35)
Total	1,30,119.80	1,41,488.42

Note : The balances disclosed relating to unsecured loans are derived from the repayment schedules. However, the year-end balances relating to unsecured loans borrowed by the Company have not been confirmed by the respective financial institutions and banks.

*** - Secured loans From Other Financial Institutions**

Particulars -	Security, Interest Rate and Terms of Repayment	As at March 31, 2025	As at March 31, 2024
SIEMENS FINANCIAL SERVICES	Secured against plant and machinery, Interest at 12.75%. Repayable in 48 equated monthly instalments commencing 17/12/2022.	13,472.01	20,530.54

**** - Unsecured loans From Banks**

Particulars -	Security, Interest Rate and Terms of Repayment	Outstanding as at March 31, 2025	Outstanding as at March 31, 2024
HDFC Bank	Interest rate at 14.75%. Repayable in 36 equated monthly instalments commencing 06/11/2022.	1,151.69	2,910.71
ICICI Bank -2	Interest rate at 15.75%. Repayable in 36 equated monthly instalments commencing 05/11/2022.	1,726.79	4,343.93
Axis Bank	Interest rate at 15.50%. Repayable in 36 equated monthly instalments commencing 20/10/2022.	773.75	2,206.42
Yes Bank	Interest rate at 16.50%. Repayable in 36 equated monthly instalments commencing 08/11/2022.	938.96	2,353.83
Standard Chartered Bank	Interest rate at 15.50%. Repayable in 36 equated monthly instalments commencing 01/04/2023.	2,893.30	5,373.67
Deutsche bank	Interest rate at 15%. Repayable in 36 equated monthly instalments commencing 05/04/2023 for the original loan and top-up loan is repayable as per the updated repayment schedule.	7,008.50	3,581.61
Total		14,493.00	20,770.18

***** - 'Unsecured loans From Other Financial Institutions**

Particulars -	Security, Interest Rate and Terms of Repayment	As at March 31, 2025	As at March 31, 2024
Bajaj Finance	Interest rate at 18%. Repayable in 36 equated monthly instalments commencing 02/08/2023.	1,724.63	2,931.24
Fullerton India Credit Co Ltd	Interest rate at 16%. Repayable in 36 equated monthly instalments commencing 05/02/2024.	3,354.04	4,814.34
Unity Small Finance Ltd	Interest rate at 16.50%. Repayable in 12 equated monthly instalments commencing 04/03/2024.	-	4,706.19
IIFL	Interest rate ranges between 16% & 17%. Repayable in 120 equated monthly instalments commencing 05/05/2019.	4,297.02	5,056.50
Tata Capital	Interest rate at 16%. Repayable in 36 equated monthly instalments commencing 03/10/2022.	1,167.42	2,933.29
Ugro Capital Ltd	Interest rate at 16.50%. Repayable in 12 equated monthly instalments commencing 03/04/2024.	451.80	5,000.00
Ambit Finvest Private Limited	Interest rate at 17%. Repayable in 36 equated monthly instalments commencing 01/06/2024.	3,976.49	-
Unity Small Finance Ltd-758	Interest rate at 16.50%. Repayable in 12 equated monthly instalments commencing 30/10/2024.	2,257.55	-
Clix Capital Services Pvt Ltd	Interest rate at 17.00%. Repayable in 24 equated monthly instalments commencing 05/06/2024.	2,350.00	-
Total		19,578.95	25,441.56



BIOMYLZ PRIVATE LIMITED
Notes to the Balance Sheet as at March 31, 2025

**** - Terms of Unsecured Loan from Directors (Refer Note 30 for Related Party Disclosures)

Particulars -	Security, Interest Rate and Terms of Repayment	As at March 31, 2025	As at March 31, 2024
Rahul Narayana Reddy (Disputed)		53,720.00	53,720.00
P K Padmavathi - Loan 1 (Disputed)		39,694.50	39,694.50
P K Padmavathi - Loan 2 (Disputed)		12,000.00	12,000.00
Total		1,05,414.50	1,05,414.50

The Company has obtained certain unsecured loans from directors for which no written agreements exist and the terms of repayment have not been defined.

In respect of the loan from Mrs. P. K. Padmavathi (Loan 2), interest at the rate of 12% per annum was provided up to June 2022. The chargeability of interest on these loans has been disputed by other directors. Accordingly:

a) The disputed interest receivable has been disclosed under Note 13 – Other Non-Current Assets as “Disputed Interest to be Recovered”

b) The related interest payable has been disclosed under Note 8 – Other Current Liabilities as “Interest payable on unsecured loans from directors”.

The aforesaid loans have been disclosed in the financial statements as “Disputed”. Refer Note 26 for pending litigations

6 Short-Term Borrowings	As at March 31, 2025	As at March 31, 2024
<u>Unsecured Borrowings</u>		
- Current maturities of long-term debts	22,838.65	30,668.35
Total	22,838.65	30,668.35

7 Trade Payables	As at March 31, 2025	As at March 31, 2024
Outstanding dues to creditors	99,508.71	1,33,222.95
Total	99,508.71	1,33,222.95

* - There are no disputed dues

Ageing for trade payables outstanding as at March 31, 2025 is as follows:

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i. Undisputed dues- MSME*	-	-	-	-	-
ii. Undisputed dues- Others	98,607.77	429.96	470.97	-	99,508.71
Total	98,607.77	429.96	470.97	-	99,508.71


Ageing for trade payables outstanding as at March 31, 2024 is as follows:

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i. Undisputed dues- MSME*	-	-	-	-	-
ii. Undisputed dues- Others	1,27,686.75	1,899.71	131.13	3,505.36	1,33,222.95
Total	1,27,686.75	1,899.71	131.13	3,505.36	1,33,222.95

* - The disclosure in respect of the amounts payable to MSME enterprises have been made in the financial statement based on information received and available with the Company. Further in view of the Management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act is not expected to be material. The Company has not received any claim for interest from any supplier as at the Balance Sheet date.

8 Other Current Liabilities	As at March 31, 2025	As at March 31, 2024
Advances from customers	9,259.30	30,176.46
Payable to employees	3,111.64	3,681.75
Interest payable on unsecured loans from directors (Refer Note 5)	2,308.75	2,308.75
Statutory dues payable	255.82	239.76
Withholding tax payable	3,220.07	1,518.77
Total	18,155.58	37,925.49

9 Short Term Provisions	As at March 31, 2025	As at March 31, 2024
Income Tax Provision (Net of Advance Tax and TDS Receivable)	4,373.60	7,744.04
Total	4,373.60	7,744.04



BIOMYLZ PRIVATE LIMITED
Notes to the Balance Sheet as at March 31, 2025

	As at March 31, 2025	As at March 31, 2024
11 Deferred Tax Asset/(Liability)		
- Property, Plant & Equipment: Impact of difference between tax depreciation and depreciation charged for the financial reporting	1,587.22	470.03
Total	1,587.22	470.03
12 Long-Term Loans and Advances (Unsecured and Considered good)		
Rent Deposit	10,315.00	10,315.00
Gas Deposit	18.05	18.05
Total	10,333.05	10,333.05
13 Other Non-Current Assets		
Disputed interest receivable (Refer Note 5)	2,100.00	2,100.00
Total	2,100.00	2,100.00
14 Inventories *		
Raw Materials **	77,401.91	1,34,021.82
Work-in-Progress and finished Stocks	94,565.35	69,117.75
Total	1,71,967.26	2,03,139.57

* - valued at cost except non-moving inventory. Not tested for realizable value.

** - includes non-moving inventory of Rs. 42,975.89 thousands (39,045.62 thousands) valued at sale price and reduced by estimated margins.

	As at March 31, 2025	As at March 31, 2024
15 Trade Receivables		
Unsecured considered good	44,382.54	79,517.39
Total	44,382.54	79,517.39

* - There are no disputed dues

Undisputed net Trade Receivables net of provisions - Ageing


Particulars	As at March 31, 2025			As at March 31, 2024		
	Considered Good	Considered Doubtful	Total	Considered Good	Considered Doubtful	Total
Less than 6 Months	30,377.63	-	30,377.63	56,082.80	-	56,082.80
6 months - 1 year	4,053.18	-	4,053.18	7,836.50	-	7,836.50
1 - 2 Years	1,509.22	53.88	1,563.10	6,893.85	2,610.87	9,504.72
2 - 3 Years	-	2,207.40	2,207.40	-	1,151.92	1,151.92
More than 3 Years	-	6,181.22	6,181.22	-	4,941.45	4,941.45
Total	35,940.04	8,442.50	44,382.54	70,813.14	8,704.23	79,517.39

	As at March 31, 2025	As at March 31, 2024
16 Cash and Cash Equivalents		
Balances with Banks - in current accounts*	3,800.41	22,971.29
Cash on hand	7.69	21.46
Balances with Banks - Fixed Deposits(Margin money for BG)*	34.21	34.21
Total	3,842.31	23,026.95

* - For a few bank accounts, banks have confirmed neither the balances nor provided the statement of accounts. These accounts have a total balance of Rs 3,404.16 thousands as at March 31, 2025 and as at previous year end.

	As at March 31, 2025	As at March 31, 2024
17 Other Current assets (Unsecured and considered good)		
Balances with Government Authorities		
Goods and Services Tax	37,874.37	25,640.96
RoDTEP Receivable	1,190.65	438.39
Advances to vendors *	8,532.36	11,777.15
Advances to Employees	23.00	278.50
Others - TDS Receivable from Vendors/Financial Institutions	650.38	358.99
Total	48,270.75	38,493.99

* - Includes advances of Rs. 882.02 thousands (P.Y Rs. 882.02 thousands) doubtful of recovery.




BIOMYLZ PRIVATE LIMITED

Notes to the Statement of Profit and Loss for the year ended March 31, 2025

		For the year ended March 31, 2025	For the year ended March 31, 2024
18	Revenue from Operations		
	Sale of Products		
	Domestic sales	2,63,058.36	3,57,388.44
	Export sales(Refer Note 30 for Related Party Disclosures)	4,24,996.30	2,24,837.26
	Other Operating Revenues	12,331.21	4,123.98
	Total	7,00,385.87	5,86,349.68
19	Other Income		
	Sale of Scrap	472.06	-
	Liabilities no longer payable, written back (Refer Note 31(d))	3,639.80	-
	Profit on sale of assets	522.10	-
	Total	4,633.97	-
20	Cost of Raw Material Consumed		
	Opening Stock of Raw Material	1,34,021.82	50,811.65
	Add: Purchases net rejections(Refer Note 30 for Related Party Disclosures)	3,51,586.74	4,23,379.62
		4,85,608.56	4,74,191.27
	Less: Closing Stock of Raw Material	77,401.91	1,34,021.82
	Total	4,08,206.65	3,40,169.44
21	(Increase)/Decrease of Finished Goods & WIP		
	Opening balance of Finished Goods & WIP	69,117.75	42,994.48
	Closing balance of Finished Goods & WIP	94,565.35	69,117.75
		(25,447.61)	(26,123.27)
22	Employee Benefit Expenses*		
	Salaries, wages and bonus(Refer Note 30 for Related Party Disclosures)	44,875.53	40,380.94
	Contributions to ESI, PF and other funds	1,511.40	1,570.11
	Staff Welfare Expenses	5,931.06	3,239.80
	Total	52,317.99	45,190.84
* - The company has not provided for gratuity either on full cost basis or on actuarial valuation basis.			
23	Finance Cost		
	Interest Expenses		
	- to banks and financial institutions*	8,793.10	9,069.26
	Bank Charges and Processing Charges	800.15	1,187.02
	Total	9,593.25	10,256.28


* - TDS has not been deducted on interest to a few financial institutions, as the Company has serviced the loan through the issuance of post-dated cheques.



BIOMYLZ PRIVATE LIMITED

Notes to the Statement of Profit and Loss for the year ended March 31, 2025

24	Depreciation and Amortisation Expenses	For the year ended	For the year ended
		March 31, 2025	March 31, 2024
	Depreciation	13,999.39	13,054.73
	Total	13,999.39	13,054.73
25	Other expenses	For the year ended	For the year ended
		March 31, 2025	March 31, 2024
	Operating expenses		
	Labour Charges paid	74,605.20	61,120.41
	Printing Charges	12,759.79	8,116.02
	Utilities	16,012.54	14,662.72
	Factory repairs and maintainance	11,304.28	7,684.61
	Transporation, Freight Inwards, Handling Charges	5,149.61	2,256.90
	Testing charges and service charges	18,650.23	11,415.31
	Total (A)	1,38,481.66	1,05,255.98
	Administration Expenses		
	Rent	14,991.50	17,837.00
	Professional charges	4,295.05	5,764.12
	Security charges	1,847.83	1,701.47
	Repairs & Maintenance		
	Computers	523.55	148.35
	Office	63.53	70.50
	Vehicle	64.44	21.40
	Travelling expenses	1,994.51	3,244.46
	Rates, taxes and fees	399.47	3,962.13
	Postage and courier Charges	1,291.58	1,001.94
	Insurance	797.36	596.80
	Membership and subscription	39.13	284.48
	Printing and Stationery	858.37	514.51
	Telephone Expenses	95.72	76.57
	Other Office Expenses	47.42	125.67
	Total (B)	27,309.44	35,349.41
	Selling and Distibution Expenses		
	Discounts, Commission and brokerage	28,202.26	16,774.22
	Advertisements and Publicity	89.46	96.47
	Business Promotion	436.53	415.33
	Freight outwards and clearing charges	35,210.90	13,908.62
	Loss due to Foreign exchange fluctuation (Net)	2,573.98	3,969.44
	Total (C)	66,513.12	35,164.07
	Payment to Auditors		
	- as statutory audit fee & Tax audit fee	440.00	440.00
	- for other services	121.00	331.00
	Total (D)	561.00	771.00
	Total of Other Expenses (A) + (B) + (C) + (D)	2,32,865.22	1,76,540.46



BIOMYLZ PRIVATE LIMITED**Notes to the Statement of Profit and Loss for the year ended March 31, 2025****26 Pending Litigations**

a) One of the shareholders and directors of the Company, has filed a Company Petition before the NCLT, Bengaluru, treating his investment as a loan. The said petition was admitted by NCLT. Subsequently, the Company challenged the said order before the NCLAT, Chennai by filing appeal. The NCLAT has stayed the operation of the NCLT order. The Company Appeal is currently pending disposal.

b) Two of the shareholders and directors of the Company have filed a Company Petition under Sections 241 and 242 of the Companies Act, 2013 before the NCLT, Bengaluru, against the other shareholders and directors of the Company. The said petition is currently pending disposal

27 Earning per share (EPS)	For the year ended	
	March 31, 2025	March 31, 2024
Profit after tax	9,298.76	17,630.49
Weighted average number of paid-up shares outstanding	50,000	50,000
Basic/diluted profit per share (Rs.)	185.98	352.61
Nominal value of equity share (Rs.)	10.00	10.00

28 Additional Information disclosure	For the year ended	
	March 31, 2025	March 31, 2024
Expenditure in Foreign Currency		
Travel	1,821.13	1,869.08
Commission	13,371.26	5,676.61
Earnings in Foreign Currency		
Export sales(Refer Note 30 for Related Party Disclosures)	4,32,231.77	2,24,837.26
Other Operating Revenues	1,977.32	5,169.90
Import in CIF basis		
Purchase of Materials	17,361.03	3,298.68



BIOMYLZ PRIVATE LIMITED
Notes forming part of financial statements for the year ended March 31, 2025

10 Property, Plant and Equipment and Intangible Assets

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at April 01, 2024	Additions 01-04-2024 to 31-03-2025	Deletions/ Impairment 31-03-2025	As at March 31, 2025	As at April 01, 2024	Additions 01-04-2024 to 31-03-2025	Deletions 31-03-2025	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025
<u>Tangible Assets:</u>										
Computers	1,749.04	213.81	-	1,962.85	1,643.31	148.01	-	1,791.31	105.74	171.54
Furniture & Fixtures	35,347.33	519.75	-	35,867.08	15,957.71	3,387.98	-	19,345.69	19,389.61	16,521.39
Leasehold Premises	2,214.76	902.90	-	3,117.66	986.49	97.65	-	1,084.14	1,228.27	2,033.52
Office Equipment	4,342.37		-	4,342.37	2,971.25	274.87	-	3,246.12	1,371.13	1,096.25
Plant and Machinery	72,089.26	20,206.62	522.10	91,773.78	32,630.43	9,857.35	522.10	41,965.68	39,458.84	49,808.11
Vehicles	739.46	-		739.46	142.33	87.85	-	230.18	597.13	509.28
Total - (A)	1,16,482.22	21,843.08	522.10	1,37,803.20	54,331.51	13,853.71	522.10	67,663.12	62,150.71	70,140.08
<u>Intangible Assets:</u>										
Software	460.00	-		460.00	287.79	145.68		433.47	172.21	26.53
Total - (B)	460.00	-	-	460.00	287.79	145.68	-	433.47	172.21	26.53
Grant Total- (A) + (B)	1,16,942.22	21,843.08	522.10	1,38,263.20	54,619.30	13,999.39	522.10	68,096.59	62,322.92	70,166.61

Note : Depreciation has been calculated asset block-wise, as the individual asset-wise breakdown of fixed assets is in progress.



BIOMYLZ PRIVATE LIMITED
Notes forming part of financial statements for the year ended March 31, 2025

Ratios

Ratio	Numerator	Denominator	For the year ended March 31, 2025	For the year ended March 31, 2024	% Variance	Reason for Variance if more than 25%
Current ratio (in times)	Total current assets	Total current liabilities	1.85	1.64	12.83%	NA
Debt equity ratio (in times)	Long term borrowings+Short term borrowings	Share capital + Reserves & surplus	1.97	2.52	-21.79%	NA
Debt service coverage ratio (in times)	PBT+Depreciation+Finance cost	Finance cost + Long term borrowings + Short term borrowings	0.23	0.28	-17.73%	NA
Return on equity ratio (%)	Profit after tax	Share capital + Reserves & surplus	11.97%	25.79%	-53.57%	Due to increase in the Profit
Inventory turnover ratio	Revenue from operations	Average Inventory	4.07	2.89	41.10%	Due to Increase in Revenue and decrease in the Inventory
Trade receivable turnover ratio (In times)	Revenue from operations	Trade Receivable	15.78	7.37	114.01%	Due to Increase in Revenue and decrease in the Trade Receivable
Trade payables turnover ratio (In times)	Cost of Purchases	Trade payable	3.53	3.18	11.18%	NA
Net Capital turnover ratio (In times)	Revenue from operations	Working capital (i.e. Total current assets less Total current liabilities)	5.67	4.36	30.11%	Due to increase in the Revenue from operation
Net profit ratio (%)	Profit after tax	Revenue from operations	1.33%	3.01%	-55.85%	
Return on capital employees (%)	PBT+Finance cost	Share capital + Reserves & surplus + Long tem borrowings+ Short term borrowings	10.01%	15.60%	-35.85%	Due to decrease in profit
Return on investment (%)	Dividend received + Interest received	Non current investment + Fixed deposits	Not applicable since no Non current investment & Fixed deposits		0.00%	NA



BIOMYLZ PRIVATE LIMITED

Notes forming part of financial statements for the year ended March 31, 2025

30 Related parties with whom transactions have taken place during the year and their relationship :

(i) Name of the related party	Description of the relationship
Srisailan Krishnamurthy	Director
Rahul Narayana Reddy	Director
Srinivasa Raghavendra	Director
Vasanth Samaga	Director
P K Padmavathi	Director
BioMylz USA INC	Entity having common control

(ii) Summary of transactions with related parties during the year

Nature of transactions/ Name of related party	For the year ended March 31, 2025	For the year ended March 31, 2024
Managerial remuneration		
Srisailan Krishnamurthy	5,089.65	4,883.26
Srinivasa Raghavendra	5,089.65	4,883.26
Vasanth Samaga	5,089.65	4,883.26
Rahul Narayana Reddy	1,882.28	1,852.76
Sale of Goods/Services		
BioMylz USA INC	79,995.45	13,007.20
Sale of Plant and Machinery		
BioMylz USA INC	522.10	-
Purchase Goods/Services		
BioMylz USA INC	5633.29	-

(iii) Balances as at the year end

Nature of transactions/ Name of related party	As at March 31, 2025	As at March 31, 2024
Borrowings - Due to Related Parties		
Rahul Narayana Reddy	(53,720.00)	(53,720.00)
P K Padmavathi	(51,694.50)	(51,694.50)
Interest on unsecured loan		
P K Padmavathi	(2,308.75)	(2,308.75)
Receivables/(Advance Received)		
BioMylz USA INC	8,670.21	(1,676.80)


- 31** a) Trade receivables, Advance to Vendors, Trade Payables & Advance from customers considered in the financials are subject to confirmation.
b) The company has not restated the carrying value of foreign exchange receivables and payables at the financial year-end as required under AS 11.
c) Certain export receivables of the Company have not yet been realized within the stipulated period and require approval/extension from the relevant regulatory authorities. The Company is in the process of obtaining/regularizing the necessary approvals.
d) A few old outstanding payable balances have been written back and the same is disclosed under 'Other Income' as 'Liabilities no longer payable, written back' in Note 19.

32 Title Deeds of Immovable Property

The company does not hold any immovable property and hence the disclosure requirement as per the revised Schedule III Division I is not applicable.

33 Expenditure on corporate social responsibility activities

As per Section 135 of the Companies Act, 2013, Company needs to spend 2% of Net profit for CSR activities meeting the threshold specified thereon. Since, the Company does not meet the criteria specified in Section 135 of the Companies Act, 2013, the Company is not required to spend any amount on activities related to corporate social responsibility for the period ended March 31, 2025.



BIOMYLZ PRIVATE LIMITED

Notes forming part of financial statements for the year ended March 31, 2025

34 Other Regulatory Disclosures

Undisclosed Income

There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

Details of Crypto Currency or Virtual Currency

The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year and hence disclosure under this heading is not applicable.

Segment reporting

The company does not have multiple segments during the year & hence segment wise disclosures have not been made.

Revaluation by Registered Valuer

The Company has not revalued its Property, Plant and Equipment during the year.

Benami Transactions

No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

Compliance with approved scheme of Arrangements

The Company has not entered into any approved Scheme of Arrangements by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013, hence disclosure under this heading is not applicable.

Compliance with number of layers of companies

The Company has not made any investments in other companies and hence disclosure under this heading is not applicable.

Registration of charges or satisfaction with Registrar of Companies

The Company has no charges or satisfaction pending to be registered with Registrar of Companies beyond the statutory period, and hence disclosure under this heading is not applicable.

Wilful Defaulter

The Company has not been declared a wilful defaulter by any bank or financial Institution, and hence disclosure under this heading is not applicable.

Relationship with Struck off Companies

The Company has no transactions during the reporting period with any of the struck off companies.

35 Previous year figures

Previous year figures have been regrouped/rearranged/reclassified wherever necessary. The financial statement are presented in Indian Rupees thousand except otherwise stated.

As per our report of even date

For Venkatesh & Raghavendra

Chartered Accountants

Firm Regn No : 0193675



CA Raghavendra D

Partner

Membership No. 212056

UDIN: 25212056BMJTMZ6473


Place : Bengaluru

Date : 22-09-2025

For and on behalf of the Board of

Biomylz Private Limited

For BioMylz Pvt. Ltd.


Director

Vasanth Samaga

Director

DIN: 07321429

For BioMylz Pvt. Ltd.


Director

Srisailan Krishnamurthy

DIN : 03614475